Amgen Q4 Earnings: Strong Pipeline And Label Expansions Justify Buy Rating
Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read why AMGN stock is a Buy.
Marketing2h
Your Quickest Path to Master B2B Marketing
Your go-to for B2B Marketing Training and Consulting backed by data science, psychology, and—our secret weapon—real-world experience. Join 350,000+ marketers who rely on MarketingProfs for B2B ...